Tumor suppressor p53 gene: A potential target for cancer therapy?;Le gene suppresseur de tumeur p53: Une cible possible pour la therapie anticancereuse ?

Bulletin du Cancer

Volumn 84, Issue 7, 1997, Pages 753-756

  Soussi, Thierry ^a  

^a INSTITUT CURIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53; ANTINEOPLASTIC AGENT; E1B PROTEIN;

CANCER THERAPY; GENE TARGETING; HUMAN; REVIEW; TUMOR SUPPRESSOR GENE; ANIMAL; APOPTOSIS; CELL DIVISION; DNA DAMAGE; DRUG RESISTANCE; GENE THERAPY; GENETICS; IMMUNOTHERAPY; METABOLISM; MOUSE; MUTATION; NEOPLASM;

ADENOVIRUS E1B PROTEINS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL DIVISION; DNA DAMAGE; DRUG RESISTANCE, NEOPLASM; GENE THERAPY; GENES, P53; HUMANS; IMMUNOTHERAPY; MICE; MUTATION; NEOPLASMS;

EID: 0031178899     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Greenblatt MS, BennettWP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene : clues to cancer etiology and molecular pathogenesis. Cancer Res 1994 ; 54 : 4855-78.
2. Bischoff JR, Kim DH, Williams A, Heise C, Horn S, Muna M, Ng L, Nye JA, Sampson-Johannes A, Fattaey A, McCormick F. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996 ; 274 : 373-6.
3. Roth JA, Nguyen D, Lawrence DD, Kemp BL, Carrasco CH, Ferson DZ, Hong WK, Komaki R, Lee JJ, Nesbitt JC, Pisters KMW, Putnam JB, Schea R, Shin DM, Walsh GL, Dolormente MM, Han CI, Martin FD, Yen N, Xu K, Stephens LC, McDonnell TJ, Mukhopadhyay T, Cai D. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nature medicine 1996 ; 2 : 985-91.
4. Maltzman W, Czyzyk L. UV irradiation stimulates levels of p53 cellular tumor antigen in non transformed mouse cells. Mol Cell Biol 1984 ; 4 : 1689-94.
5. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991 ; 51 : 6304-11.
6. Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 1991 ; 352 : 345-7.
7. Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 1992 ; 89 : 7491-5.
8. Fritsche M, Haessler C, Brandner G. Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. Oncogene 1993 ; 8 : 307-18.
9. Lane D. p53, guardian of the genome. Nature 1992 ; 358 : 15-6.
10. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA, Butel JS, Bradley A. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992 ; 356 : 215-21.
11. Malkin D, Li FP, Strong LC, Fraumeni JF, Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA, Friend SH. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990 ; 250 : 1233-8.
12. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993 ; 74 : 957-67.
13. Eliopoulos AG, Kerr DJ, Herod J, Hodgkins L, Krajewski S, Reed JC, Young LS. The control of apoptosis and drug resistance in ovarian cancer : influence of p53 and bcl-2. Oncogene 1995 ; 11 : 1217-28.
14. Fan SJ, E-Deiry WS, Bae I, Freeman J, Jondle D, Bhatia K, Fornace AJ, Magrath I, Kohn KW, O'Connor PM. p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res 1994 ; 54 : 5824-30.
15. Fan SJ, Smith ML, Rivet DJ, Duba D, Zhan QM, Kohn KW, Fornace AJ, O'Connor PM. Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res 1995 ; 55 : 1649-54.
16. O'Connor PM, Jackman J, Jondle D, Bhatia K, Magrath I, Kohn KW. Role of the p53 tumor suppressor gene in cell cycle arrest and radiosensitivity of burkitt lymphoma cell lines. Cancer Res 1993 ; 53 : 4776-80.
17. Xia F, Wang X, Wang YH, Tsang NM, Yandell DW, Kelsey KT, Liber HL. Altered p53 status correlates with differences in sensitivity to radiation-induced mutation and apoptosis in two closely related human lymphoblast lines. Cancer Res 1995 ; 55 : 12-5.
18. Wu GS, El-Deiry WS. Apoptotic death of tumor cells correlates with chemosensitivity, independent of p53 or Bcl-2. Clinical Cancer Research 1996 ; 2 : 623-33.
19. Wu GS, El-Deiry WS. p53 and chemosensitivity. Nature medicine 1996 ; 2 : 255-6.
20. Benhattar J, Cerottini JP, Saraga E, Metthez G, Givel JC. p53 mutations as a possible predictor of response to chemotherapy in metastatic colorectal carcinomas. Int J Cancer 1996 ; 69 : 190-2.
21. Delia D, Mizutani S, Lamorte G, Goi K, Iwata S, Pierotti MA. p53 activity and chemotherapy. Nature medicine 1996 ; 2 : 724-5.
22. Elledge RM, Gray R, Mansour E, Yu YY, Clark GM, Ravdin P, Osborne CK, Gilchrist K, Davidson NE, Robert N, Tormey DC, Allred DC. Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemotherapy with cyclophosphamide, methotrexate, fluorouracil, and prednisone for breast cancer. J Natl Cancer Inst 1995 ; 87 : 1254-6.
23. Garzetti GG, Ciavattini A, Provinciali M, DiStefano G, Lucarini G, Goteri G, Biagini G. Expression of p53 and apoptosis of tumor cells in locally advanced cervical carcinoma after cisplatin based neoadjuvant chemotherapy. Anticancer Res 1996 ; 16 : 3229-34.
24. Hawkins DS, Demers GW, Galloway DA. Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res 1996 ; 56 : 892-8.
25. Mac Grogan G, Mauriac L, Durand M, Bonichon F, Trojani M, de Mascarel I, Coindre JM. Primary chemotherapy in breast invasive carcinoma : predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST pi. Br J Cancer 1996 ; 74 : 1458-65.
26. Nabeya Y, Loganzo F, Maslak P, Lai L, Deoliveira AR, Schwartz GK, Blundell ML, Altorki NK, Kelsen DP, Albino AP. The mutational status of p53 protein in gastric and esophageal adenocarcinoma cell lines predicts sensitivity to chemotherapeutic agents. Int J Cancer 1995 ; 64 : 37-46.
27. Rusch V, Klimstra D, Venkatraman E, Oliver J, Martini N, Gralla R, Kris M, Dmitrovsky E. Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer. Cancer Res 1995 ; 55 : 5038-42.
28. Wattel E, Preudhomme C, Hecquet B, Vanrumbeke M, Quesnel B, Dervite I, Morel P, Fenaux P. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 1994 ; 84 : 3148-57.
29. Aas T, Borresen AL, Geisler S, Smithsorensen B, Johnsen H, Varhaug JE, Akslen LA, Lonning PE. Specific p53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nature medicine 1996 ; 2 : 811-4.
30. Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang WW, Owenschaub LB, Roth JA. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res 1994 ; 54 : 2287-91.
31. Blagosklonny MV, El-Deiry WS. In vitro evaluation of a p53-expressing adenovirus as an anti-cancer drug. Int J Cancer 1996 ; 67 : 386-92.
32. Spitz FR, Nguyen D, Skibber JM, Meyn RE, Cristiano RJ, Roth JA. Adenoviral-mediated wild-type p53 gene expression sensitizes colorectal cancer cells to ionizing radiation. Clinical Cancer Research 1996 ; 2 : 1665-71.
33. Yang B, Eshleman JR, Berger NA, Markowitz SD. Wild-type p53 protein potentiates cytotoxicity of therapeutic agents in human colon cancer cells. Clinical Cancer Research 1996 ; 2 : 1649-57.
34. Fujiwara T, Grimm EA, Mukhopadhyay T, Cai DW, Owenschaub LB, Roth JA. A retroviral wild-type p53 expression vector penetrates human lung cancer spheroids and inhibits growth by inducing apoptosis. Cancer Res 1993 ; 53 : 4129-33.
35. Soussi T. The humoral response to the tumor-suppressor gene-product p53 in human cancer : implications for diagnosis and therapy. Immunol Today 1996 ; 17 : 354-6.
36. Tilkin AF, Lubin R, Soussi T, Lazar V, Janin N, Mathieu MC, Lefrere I, Carlu C, Roy M, Kayibanda M, Bellet D, Guillet JG, Bressac de Paillerets B. Primary proliferative T cell response to wild-type p53 protein in patients with breast cancer. Eur J Immunol 1995 ; 25 : 1765-9.
37. Ciernik IF, Berzofsky JA, Carbone DP. Induction of cytotoxic T lymphocytes and antitumor immunity with DMA vaccines expressing single T cell epitopes. J Immunol 1996 ; 156 : 2369-75.
38. Nijman HW, Houbiers JGA, Vanderburg SH, Vierboom MPM, Kenemans P, Kast WM, Melief CJM. Characterization of cytotoxic T-lymphocyte epitopes of a self-protein, p53, and a non-self-protein, influenza matrix - relationship between major histocompatibility complex peptide binding affinity and immune responsiveness to peptides. J Immunother 1993 ; 14 : 121-6.
39. Theobald M, Biggs J, Dittmer D, Levine AJ, Sherman LA. Targeting p53 as a general tumor antigen. Proc Natl Acad Sci USA 1995 ; 92 : 11993-7.
40. Roth J, Dittmer D, Rea D, Tartaglia J, Paoletti E, Levine AJ. p53 as a target for cancer vaccines : recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor cell challenge. Proc Natl Acad Sci USA 1996 ; 93 : 4781-6.